NDAINHALATIONGAS
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MEDICAL AIR, USP (medical air) by Connect Biopharma. Approved for idiopathic pulmonary fibrosis. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEDICAL AIR, USP is an inhalation gas product approved by the FDA on July 13, 2024, for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The product represents a novel non-pharmacological therapeutic approach to a progressive and fatal lung disease.
Growth
Early-stage growth product with competitive pressure at 30%, likely requiring rapid market penetration teams and commercial infrastructure build-out.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on MEDICAL AIR, USP at Connect Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.